Paradigm Biopharmaceuticals Limited (PBIGF)
USD 0.13
(0.0%)
USD 0.13
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 56.81 Thousand AUD | -99.91% |
| 2023 | 60.06 Million AUD | 25.33% |
| 2022 | 47.92 Million AUD | 10.65% |
| 2021 | 43.31 Million AUD | 152.21% |
| 2020 | 17.17 Million AUD | 43.68% |
| 2019 | 11.95 Million AUD | 33.67% |
| 2018 | 8.94 Million AUD | 45.61% |
| 2017 | 6.14 Million AUD | 42.12% |
| 2016 | 4.32 Million AUD | 174.77% |
| 2015 | 1.57 Million AUD | 579.51% |
| 2014 | 231.43 Thousand AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 7.47 Million AUD | -84.99% |
| 2024 Q2 | 49.82 Million AUD | 102.67% |
| 2024 Q1 | 24.58 Million AUD | -8.53% |
| 2024 Q4 | 7.47 Million AUD | 0.0% |
| 2024 FY | 64.4 Million AUD | 7.22% |
| 2023 Q2 | 32.21 Million AUD | 100.26% |
| 2023 Q4 | 26.87 Million AUD | 154.13% |
| 2023 Q1 | 16.08 Million AUD | -18.0% |
| 2023 FY | 60.06 Million AUD | 25.33% |
| 2023 Q3 | 10.57 Million AUD | -67.18% |
| 2022 Q2 | 27.13 Million AUD | 101.1% |
| 2022 Q4 | 19.61 Million AUD | 221.03% |
| 2022 FY | 47.92 Million AUD | 10.65% |
| 2022 Q3 | 6.11 Million AUD | -77.48% |
| 2022 Q1 | 13.49 Million AUD | -36.69% |
| 2021 Q4 | 21.31 Million AUD | 216.34% |
| 2021 FY | 43.31 Million AUD | 152.21% |
| 2021 Q1 | 10.45 Million AUD | -5.31% |
| 2021 Q2 | 20.74 Million AUD | 98.35% |
| 2021 Q3 | 6.73 Million AUD | -67.52% |
| 2020 Q3 | 3.67 Million AUD | -37.91% |
| 2020 FY | 17.17 Million AUD | 43.68% |
| 2020 Q2 | 5.91 Million AUD | 100.0% |
| 2020 Q1 | 2.95 Million AUD | -60.64% |
| 2020 Q4 | 11.04 Million AUD | 200.67% |
| 2019 Q4 | 7.51 Million AUD | 4.06% |
| 2019 Q1 | 2.21 Million AUD | -16.93% |
| 2019 Q2 | 2.21 Million AUD | -0.0% |
| 2019 Q3 | 7.22 Million AUD | 226.18% |
| 2019 FY | 11.95 Million AUD | 33.67% |
| 2018 Q3 | 2.66 Million AUD | 48.27% |
| 2018 FY | 8.94 Million AUD | 45.61% |
| 2018 Q4 | 2.66 Million AUD | 0.0% |
| 2018 Q2 | 1.79 Million AUD | -0.0% |
| 2018 Q1 | 1.79 Million AUD | 10.69% |
| 2017 Q3 | 1.62 Million AUD | 12.95% |
| 2017 Q2 | 1.43 Million AUD | -0.0% |
| 2017 Q1 | 1.43 Million AUD | 0.92% |
| 2017 FY | 6.14 Million AUD | 42.12% |
| 2017 Q4 | 1.62 Million AUD | 0.0% |
| 2016 Q1 | 734.32 Thousand AUD | -1.06% |
| 2016 Q3 | 1.42 Million AUD | 94.05% |
| 2016 Q4 | 1.42 Million AUD | 0.0% |
| 2016 FY | 4.32 Million AUD | 174.77% |
| 2016 Q2 | 734.32 Thousand AUD | 0.0% |
| 2015 Q2 | 305.13 Thousand AUD | -0.0% |
| 2015 Q4 | 742.18 Thousand AUD | 0.0% |
| 2015 FY | 1.57 Million AUD | 579.51% |
| 2015 Q1 | 305.13 Thousand AUD | 0.0% |
| 2014 FY | 231.43 Thousand AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| BioStem Technologies, Inc. | 22.97 Million USD | 99.753% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | 95.746% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 99.477% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 99.848% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 85.417% |
| Nascent Biotech, Inc. | 2.22 Million USD | 97.452% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 86.326% |
| Qrons Inc. | 643.67 Thousand USD | 91.174% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 93.848% |
| CSL Limited | 3.44 Billion USD | 99.998% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.901% |
| Skye Bioscience, Inc. | 13.54 Million USD | 99.581% |
| Rebus Holdings, Inc. | 664 Thousand USD | 91.444% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 99.645% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 98.873% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 99.808% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.935% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 98.845% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 78.293% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.934% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 98.052% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 96.217% |
| Mesoblast Limited | 5.9 Million USD | 99.037% |
| Marizyme, Inc. | 19.23 Million USD | 99.705% |
| Genus plc | 147.7 Million USD | 99.962% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 99.353% |
| Pharming Group N.V. | 225.49 Million USD | 99.975% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 97.227% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 95.765% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 99.319% |
| ContraFect Corporation | 56.88 Million USD | 99.9% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 98.711% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 96.158% |
| IMV Inc. | 37.7 Million USD | 99.849% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 97.964% |
| MultiCell Technologies, Inc. | 567.42 USD | -9912.337% |
| ONE Bio Corp. | 6.44 Million USD | 99.118% |
| Accustem Sciences Inc. | 3.74 Million USD | 98.484% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.934% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | 89.32% |
| Q BioMed Inc. | 3.43 Million USD | 98.347% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 99.77% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 97.838% |
| Biomind Labs Inc. | 994.18 Thousand USD | 94.286% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.943% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 96.771% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 99.154% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 96.953% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 327.248% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 96.904% |
| GB Sciences, Inc. | 1.42 Million USD | 96.001% |
| Alpha Cognition Inc. | 9.7 Million USD | 99.415% |
| HST Global, Inc. | 140.9 Thousand USD | 59.681% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 94.95% |
| Halberd Corporation | 74.84 Thousand USD | 24.091% |
| Enzolytics Inc. | 2.17 Million USD | 97.393% |
| Agentix Corp. | 1.37 Million USD | 95.858% |
| Resverlogix Corp. | 12.71 Million USD | 99.553% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 98.444% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.996% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 94.558% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 97.638% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 96.403% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 98.332% |
| AVAX Technologies, Inc. | 7.31 Million USD | 99.223% |
| Zenith Capital Corp. | 8.94 Million USD | 99.365% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.993% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -226.112% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 97.686% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | 66.875% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 97.042% |
| Kadimastem Ltd | 2.41 Million USD | 97.643% |
| Helix BioMedix, Inc. | 1.97 Million USD | 97.119% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | 68.696% |
| LadRx Corporation | 3.81 Million USD | 98.51% |
| Cell Source, Inc. | 4.32 Million USD | 98.687% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 93.848% |
| NovAccess Global Inc. | 2.46 Million USD | 97.697% |
| Affymax, Inc. | 39.38 Million USD | 99.856% |
| Itoco Inc. | 919.14 Thousand USD | 93.819% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 98.66% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 94.923% |
| Mobile Lads Corp. | 554.54 Thousand USD | 89.755% |
| CytoDyn Inc. | 18.05 Million USD | 99.685% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -125.722% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | 74.186% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 95.999% |
| SYBLEU INC | 160.87 Thousand USD | 64.686% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 96.872% |
| International Stem Cell Corporation | 5.27 Million USD | 98.922% |
| Bioxytran, Inc. | 3.82 Million USD | 98.513% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -7.921% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -179.271% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 99.843% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 96.489% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 92.279% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 98.174% |
| Neutra Corp. | 243.82 Thousand USD | 76.699% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 99.675% |
| PureTech Health plc | 144.59 Million USD | 99.961% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 99.723% |
| IXICO plc | 4.7 Million USD | 98.793% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 99.354% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.952% |
| CSL Limited | 3.89 Billion USD | 99.999% |
| Cellectis S.A. | 97.32 Million USD | 99.942% |